NASHVILLE, Tenn. / Nov 06, 2023 / Business Wire / Revance Therapeutics, Inc. (RVNC), today announced that the company will be participating in the following investor conferences.
Stifel 2023 Healthcare Conference
Chief Financial Officer, Tobin Schilke, is scheduled to participate in a fireside chat on Tuesday, November 14, 2023, at 11:30 A.M. EST, in New York City, New York.
Piper Sandler 35th Annual Healthcare Conference
Chief Executive Officer, Mark Foley, is scheduled to participate in a fireside chat on Tuesday, November 28, 2023, at 3:00 P.M. EST, in New York City, New York.
Interested parties can access the live audio webcasts for the conferences from the Investor Relations section of the company's website at www.revance.com. The webcast replays will be available after the conclusion of the live presentations for approximately 90 days.
About Revance
Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio includes DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection and the RHA® Collection of dermal fillers in the U.S. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to commercialize DAXXIFY® in China.
Revance is headquartered in Nashville, Tenn., with additional office locations in Newark and Irvine, Calif.
Learn more at www.Revance.com, www.RevanceAesthetics.com, www.DAXXIFY.com, www.hcp.DAXXIFYTherapy.com, or connect with us on LinkedIn.
“Revance” and the Revance logo, and DAXXIFY® are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA. BOTOX® is a registered trademark of Allergan, Inc.
| Last Trade: | US$2.71 |
| Daily Change: | 0.04 1.50 |
| Daily Volume: | 1,515,137 |
| Market Cap: | US$283.060M |
May 09, 2024 April 12, 2024 February 28, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
